Montesinos-Sanchis Elena, Moraga-Llop Fernando A, Soler-Palacín Pere, Oliveras-Arenas María, Larrosa Escartín M Nieves, Martínez Gómez Xavier, Figueras-Nadal Concepción
Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Enferm Infecc Microbiol Clin. 2014 Dec;32(10):647-53. doi: 10.1016/j.eimc.2013.10.013. Epub 2013 Dec 17.
To describe the use of carbapenems in children hospitalised outside intensive care and onco-haematology units, and assess adherence to a therapeutic protocol.
A retrospective observational study was conducted on the use of carbapenems between January 2009 and December 2010. The study included children with a community-acquired infectious disease or a health care-associated infectious disease, and who were admitted to paediatric areas of the Vall d'Hebron University Hospital (Barcelona, Spain), other than intensive care, neonatology and onco-haematology units. Clinical data were collected and antibiotic consumption data were provided by the Pharmacy Department.
A total of 51 episodes fulfilled the inclusion criteria. Carbapenem as initial empirical treatment was indicated in 31.4%, and applied as rescue therapy in the remainder. The instructions of the protocol were adhered to in 70.6% of the empirical and 87.5% of the targeted prescriptions (77.6% overall). A better match was found for empirical carbapenem in patients with a previous admission or underlying condition. Factors such as diagnosis, age or antibiotic use prior to admission did not affect the empirical indication of carbapenem.
The establishment of a treatment protocol with carbapenem indications in our centre since 2007 has yielded significantly better results on the appropriateness of the prescription than those obtained in other studies.
描述碳青霉烯类药物在非重症监护病房和肿瘤血液科住院儿童中的使用情况,并评估对治疗方案的依从性。
对2009年1月至2010年12月期间碳青霉烯类药物的使用情况进行了一项回顾性观察研究。该研究纳入了患有社区获得性传染病或医疗保健相关传染病、并入住巴塞罗那比索医院(西班牙)儿科病房(不包括重症监护病房、新生儿科和肿瘤血液科)的儿童。收集了临床数据,抗生素消耗数据由药剂科提供。
共有51例符合纳入标准。31.4%的病例将碳青霉烯类药物作为初始经验性治疗药物,其余作为挽救治疗药物使用。经验性处方中有70.6%、目标性处方中有87.5%(总体为77.6%)遵循了方案的指导。在有既往住院史或基础疾病的患者中,经验性使用碳青霉烯类药物的匹配度更高。诊断、年龄或入院前抗生素使用等因素不影响碳青霉烯类药物的经验性用药指征。
自2007年以来,在我们中心制定的碳青霉烯类药物治疗方案在处方合理性方面取得的结果明显优于其他研究。